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MN/CA IX protein (initially termed MN) was discovered in HeLa
cells using monoclonal antibody (mAb) M75 (Pastorekova et al,
1992). Its possible role in oncogenesis was suggested by two facts:
expression of MN/CA IX correlated with tumorigenicity of HeLa ´
fibroblast hybrids; it was detected in clinical specimens of cervical
and certain other carcinomas, but it was absent in normal tissues of
corresponding organs (Závada et al, 1993). MN/CA9 cDNA
(Pastorek et al, 1994) and gene (Opavsky et al, 1996) have been
cloned; predicted protein consists of signal peptide (SP), proteo-
glycan-related sequence (PG), carbonic anhydrase domain (CA),
transmembrane segment (TM) and short intracellular tail (IC).
MN/CA IX protein is a cell adhesion molecule; its CA is enzymati-
cally active (Zavada et al, 1997). MN/CA IX protein is almost 100%
associated with cervical carcinomas (Liao et al, 1994), with carci-
nomas of oesophagus (Turner et al, 1997) and with renal clear cell
carcinomas (Liao et al, 1997). It was also detected in a high
percentage of colorectal (Saarnio et al, 1998a) and lung (Vermylen
et al, 1999) carcinomas. Therefore, MN/CA IX is a promising
biomarker in tumour diagnostics. Characteristically, MN/CA IX in
human carcinomas is expressed ectopically; normally it is present in
stomach and bile duct mucosa (Liao et al, 1994) and in rapidly
proliferating normal cells in small intestine (Saarnio et al, 1998b).
An antigen specific for renal cell carcinomas was discovered using
mAb G250 (Oosterwijk et al, 1986) and was found to be identical
with MN/CA IX (Uemura et al, 1997). This antigen appears to be an
excellent target for immunotherapy (Steffens et al, 1997; Uemura et
al, 1997). Until now, molecular basis of involvement of MN/CA IX
in carcinogenesis has remained unclear. One of the possible leads
could be the fact that MN/CA IX is an adhesion molecule presum-
ably engaged in cell-to-cell communication (Závada et al, 1997). In
this paper we undertook the first steps towards elucidation of the
role of MN/CA IX protein in communication among the cells. We
attempted to identify its binding site for cell surface receptors. This
was facilitated by the finding that mAb M75 blocks adhesion of
cells to affinity-purified MN/CA IX protein.
MATERIALS AND METHODS
Affinity chromatography of MN/CA IX
MN/CA IX was purified by a single cycle of adsorption–elution on
sulphonamide-agarose, as described for other CAs (Falkbring 
et al, 1972). We used columns of p-aminomethylbenzene-
sulphonamide-agarose (Sigma). Columns with adsorbed MN/CA
IX were extensively washed with phosphate-buffered saline (PBS)
sodium chloride (NaCl) 8.0 g l–1, potassium chloride (KCl) 
0.2 g l–1, KH2PO4 0.2 g l–1, Na2HPO4 1.15 g l–1, pH = 7.2) and
eluted with 0.1 mM acetazolamide (Sigma). All steps of purifica-
tion were carried out at 0–5°C, pH 7.2, at physiological concentra-
tion of salts. Complete MN/CA IX+ was extracted with 1% Triton
X-100 in PBS from Vero cells infected with vaccinia virus
containing an insert of complete coding region of MN/CA IX as
described (Závada et al, 1997). Before chromatography, the extract
was diluted 1:6 with PBS and centrifuged for 1 h at 15 000 g.
Truncated MN/CA IX DTMDIC was produced from an analogous
construct except that the 3¢ downstream primer for polymerase
chain reaction (PCR) was: 5¢-CGT CTA GAA GGA ATT CAG
CTA GAC TGG CTC AGC A-3¢. MN/CA IXD was shed into the
medium, from which it was affinity purified after centrifugation as
above. All steps of purification were monitored by dot-blots.
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The following cell lines were used: HeLa, CGL1 = non-tumori-
genic hybrid HeLa ´ fibroblast, CGL3 = tumorigenic segregant
from this hybrid. The origin of the cells and growth media were
described previously (Závada et al, 1992, 1997). In addition, we
used also HT29, a cell line derived from colorectal carcinoma
(ATCC No. HBT-38).
Cell adhesion test
The conditions of the test were described previously (Zavada 
et al, 1997). Briefly, 1 mg ml–1 of purified MN/CA IX in 50 mM
mono/bicarbonate buffer, pH 9.2, was adsorbed in 30-ml drops on
the bottom of bacteriological 5-cm Petri dishes for 1.5 h. Then the
drops were removed by aspiration and the dishes were 3 ´ rinsed
with PBS and blocked with 50% fetal calf serum (FCS) in culture
medium for 30 min. There were two variants of the test. In the first
one (Figure 2), the whole bottom of the Petri dish was blocked
with 50% of FCS, and the dishes were seeded with 5 ml of cell
suspension (105 cells ml–1). After overnight incubation, the
cultures were rinsed with PBS, fixed and stained. In the other
variant (Figure 4), only the area of adsorbed MN/CA IX was
blocked and on top of MN/CA IX dots were added 30-ml drops of
cell suspension in growth medium, containing added oligopeptides
(or control without peptides). After incubation, rinsing and fixa-
tion, the cultures were stained with 0.5% Trypan blue in 50 mM
Tris buffer pH 8.5 for 1 h, rinsed with water and dried. Stained
areas of attached cells were extracted with 10% acetic acid, the
extracts transferred to 96-well plates and absorbance was
measured at 630 nm on a microplate reader.
ELISA
Purified GST-MN (Závada et al, 1993) at concentration 10 ng ml–1
in carbonate buffer pH 9.2 was adsorbed for 3 h in Maxisorb strips
(NUNC). After washing and blocking (1 h) with 0.05% Tween-20
in PBS, 50 ml well–1 of the antibody + antigen mixtures were
added. Final dilution of mAb M75 ascites fluid was 10–6; concen-
tration of the peptides varied according to their affinity for M75 so
as to allow determination of 50% end point. These mixtures were
adsorbed for 1.5 h, followed by washing with Tween–PBS. Bound
antibody was detected by antimouse IgG conjugate with peroxi-
dase (SwAM-Px, SEVAC, Prague), diluted 1:1000. In the colour
reaction OPD (o-phenylenediamine dihydrochloride, Sigma) 1 mg
ml–1 in 0.1 M citrate buffer pH 5.0 was used. To this hydrogen
peroxide (H2O2) was added to final concentration 0.03%. This
system is balanced so as to allow assay for antigen competing for
M75 (Figure 3) as well as for peptides binding to the epitope of
immobilized GST-MN (Figure 4).
Peptides
The peptides used in this study were prepared by the solid-phase
method (Merrifield, 1995) using the Boc/Bzl strategy. The peptide
acids were prepared on PAM-resin and peptide amides on MeBHA
resin. Deprotection and splitting from the resin was done by liquid
hydrogen fluoride. The peptides were purified by C18 reverse
phase high-performance liquid chromatography (RP HPLC) and
characterized by amino acid analysis and FAB MS spectroscopy.
Western blots
MN/CA IX antigens from polyacylamide gel electrophoresis
(PAGE) gels were transferred to polyvinyl difluoride (PVDF)
membranes (Immobilon P, Millipore) and developed with M75,
followed by SwAM-Px (see above) and diaminobenzidine (Sigma)
with H2O2. For dot-blots we used nitrocellulose membranes.
Phage display
Ph.D.-7 Phage Display Peptide Library kit was used for screening
as recommended by manufacturer (New England Biolabs). A 96-
well plate was coated with peptide F (legend to Figure 3).
Biopanning was carried out by incubating 2 ´ 1011 phage with
target coated plate for 1 h. Unbound phages were washed away
with TBST (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.1% Tween-
20) and specifically bound phages were eluted with M75 antibody
(2 mg in 100 ml of TBS per well). Eluted phage was amplified and
used for additional binding and amplification cycles to enrich the
pool in favour of binding sequence. After 5 rounds, individual
clones were picked, amplified and sequenced using T7 sequencing
kit (Pharmacia).
RESULTS
Affinity chromatography of MN/CA IX protein
For purification of MN/CA IX protein we decided to use affinity
chromatography on sulphonamide-agarose column, described
previously for other CAs (Falkbring et al, 1972). The advantages
of this method are simplicity and the fact that the whole procedure
is carried out under non-denaturing conditions. Vaccinia virus
vector with an insert of the complete MN/CA9 cDNA, or with trun-
cated cDNA (lacking transmembrane and intracellular domains)
was employed as a source of MN/CA IX protein.
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Figure 1 PAGE and Western blot analysis of MN/CA IX protein. Lanes 
1–3 = gel stained with Coomassie Blue; lanes 4–8 = blots developed with
mAb M75 and immunoperoxidase. Lane 1 = Mr reference proteins; lane 2 =
purified MN/CA IX DTM, IC, 1.25 mg; lane 3 = purified MN/CA IX+, 2 mg; lane
4 = purified MN/CA IX DTM, IC, 0.125 mg; lane 5 = purified MN/CA IX+, 
0.2 mg; lane 6 = extract from HT29 cells, 50 ml; lane 7 = extract from CGL3
cells, 50 ml; lane 8 = extract from HeLa cells, 50 mlA single cycle of adsorption – elution yielded relatively pure
proteins (Figure 1): MN/CA IX+ gave 2 bands of 54 and 58 kDa,
MN/CA IXD of 54.5 and 56 kDa. These proteins strongly reacted
with mAb M75 on Western blots. In extracts from HeLa, CGL3
and HT29 the blot revealed 2 bands of the same size as MN/CA
IX+ purified from vaccinia virus construct.
Adhesion of cells to MN/CA IX protein
MN/CA IX immobilized on hydrophobic plastic enabled attach-
ment, spreading and growth of cells (Figure 2). Extremely low
concentrations of MN/CA IX corresponding to 1 mg ml–1 of 
purified protein in adsorption buffer were sufficient to cause this
effect; other cell adhesion molecules are used in 10–50 ´ higher
concentrations. Only complete MN/CA IX protein was active in
cell adhesion test, truncated MN/CA IX did not support cell adhe-
sion at all or it showed only a low adhesion activity and in some
instances it even acted as a cell ‘repellent’.
Treatment of the dots of immobilized MN/CA IX with mAb
M75 abrogated its capacity to attach the cells, but the control mAb
M16, irrelevant for MN/CA IX had no effect. Blocking of cell
attachment by M75 shows that the epitope is identical to or over-
lapping with the binding site of MN/CA IX for cell receptors.
Identification of the epitope recognized by Mab M75
Preliminary mapping of M75 epitope employing partial sequences
of extracellular parts of MN/CA9 cDNA expressed from bacterial
vectors and tested on Western blots located it in PG region. For
exact mapping, our strategy was to synthesize partially overlap-
ping oligopeptides of 15–25 aa covering the PG domain and test
them in competition ELISA with M75. According to the results,
this was followed by a series of 6–12 aa oligopeptides. A major
part of the PG domain consists of a sixfold tandem repeat of six aa
(aa 61–96); four repeats are identical (GEEDLP) and two contain
two aa exchanged (SEEDSP and REEDPP) (Opavsky et al, 1996).
Figure 3 shows the result of competition ELISA with recombi-
nant MN/CA IX and oligopetides synthesized according to partial
sequences of the PG region. MN/CA IX+ and D produced in
mammalian cells (proteins A and B) possessed a higher serolog-
ical activity than any other protein or peptide included in this
experiment; protein C–fusion protein GST-MN synthesized in
bacteria was less active. Peptides D, E, F and G are spanning the
PG region. Peptides D and F caused 50% inhibition at 1 ng ml–1.
These two oligopeptides are mutually non-overlapping, thus the
epitope is repeated in both of them. Peptide E was 1000 ´ less
active, probably due to a different conformation. Peptide G was
inactive; thus it does not contain the M75 epitope.
1810 J Závada et al
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Figure 2 Adhesion of cells to the dots of MN/CA IX protein immobilized in bacteriological Petri dishes. This plasticware (not treated for use with tissue
cultures) allows no adhesion of CGL1 cells and a limited adhesion of HeLa. (A) CGL1 cells do attach and spread to the dot of adsorbed MN/CA IX. 
(B) Treatment of the dot with MAb M75 abrogates its binding capacity. (C) Treatment with MAb M16 (irrelevant for MN/CA IX) has no effect on cell attachment.
(D) HeLa cells attach to complete MN/CA IX+. (E) HeLa cells do not attach to truncated MN/CA IXDMN/CA IX protein: M75 epitope and cell-binding site 1811
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Figure 3 Competition ELISA with proteins or oligopeptides related to MN/CA IX protein. Competing proteins/peptides: (A–C) Recombinant proteins. 
(A) MN/CA IX+; (B) MN/CA IXD; (C) GST-MN; (D–G) overlapping proteins covering the PG region: (D) GGSSGEDDPLGEEDLPSEEDSPC (aa 51–72); 
(E) GEEDLPSEEDSPREEDPPGEEDLPGEC (aa 61–85); (F) EDPPGEEDLPGEEDLPGEEDLPEVC (aa 75–98); (G) EVKPKSEEEGSLKLE (aa 97–111); 
(H–M) dodecapeptides: (H) GEEDLPGEEDLP; (I) EEDLPGEEDLPG; (J) EDLPGEEDLPGE; (K) DLPGEEDLPGEE; (L) LPGEEDLPGEED; 
(M) PGEEDLPGEEDL; (N, O) oligopeptides 7 + 2 aa: (N) APGEEDLPA; (O) AGEEDLPGA. Other oligopetides tested which proved negative in competition at
100 mg ml–1 were oligopeptides 7 + 2 aa: AEEDLPGEA, AEDLPGEEA, ADLPGEEDA, ALPGEEDLA and all of the 6 + 2 aa permutations (AGEEDLPA,
AEEDLPGA, AEDLPGEA, ADLPGEEA, ALPGEEDA and APGEEDLA). In oligopeptides D, E, F and G the C-terminal amino acid was present as acid, in all
others as amide
Figure 4 Competition ELISA (A) and inhibition of cell attachment (B) by oligopeptides selected from phage display library. Peptides: 1 = AKKMKRRKA, 
2 = AITFNAQYA, 3 = ASASAPVSA, 4 = AGQTRSPLA. In all 4 peptides the C-terminal alanine was present as amide
A BThe next step for identifying the epitope was to synthesize
oligopeptides containing all circular permutations of the motif
GEEDLP repeated twice (peptides H–M), all six dodecapeptides
were serologically active (two more and four less so). Following
series of seven aa sequences, flanked by alanine on both ends
finally showed that the minimum serologically active sequence is
the oligopeptide N = APGEEDLPA. None of still shorter
oligopeptides (6 + 2 aa) competed in ELISA for M75.
It is clear that the affinity between these oligopeptides and mAb
M75 very strongly increases with the size of peptide molecule.
Attempts to demonstrate adhesion of cells to
immobilized oligopeptides
Our initial plan was to follow the pioneering work of Piersbacher
and Ruoslahti (1984). They linked tested oligopeptides to
adsorbed bovine serum albumin by cross-linking agent SPDP (N-
succinimidyl 3[pyridylhydro] propionate). This is why we added
onto the C-end of oligopeptides D, E and F (Figure 3) cysteine,
which would enable oriented linking to adsorbed albumin. We
demonstrated linking of the peptides directly in Petri dishes by
immunoperoxidase staining with M75. Unfortunately, CGL1 or
CGL3 cells adhered to control albumin treated with SPDP and
blocked with ethanolamine (in place of oligopeptides) as strongly
as to bovine serum albumin (BSA) dots with linked oligopeptides.
We were unable to abrogate this non-specific adhesion. Oligo-
peptides D, E and F adsorb only very poorly to bacteriological
Petri dishes, not allowing the cell adhesion test.
Alternatively, we tested inhibition of cell adhesion to MN/CA
IX dots by oligopeptides added to the media together with the cell
suspension, as described (Piersbacher and Ruoslahti, 1984). All
peptides listed in the legend to Figure 3 were tested at concentra-
tions 100 and 10 mg ml–1. None of them inhibited reproducibly the
adhesion of CGL1 cells.
Oligopeptides with affinity to M75 epitope which inhibit
cell adhesion to MN/CA IX
As an alternative to monoclonal antibodies, we set out to select
oligopeptides exerting affinity to M75 epitope as well as to
MN/CA IX receptor binding site from a phage display library of
random heptapeptides – Ph.D.-7. Our aim was to select phages
containing the desired heptapeptides by panning on immobilized
peptide F (see legend to Figure 3) and subsequent elution with
M75. Eluted phage was multiplied in appropriate bacteria and
subjected to four more cycles of panning and elution. From the
selected phage population, ten plaques were picked, amplified 
and the heptapeptide-coding region was sequenced. Only three
heptapeptides were represented: these, after adding alanine on
both sides, are nonapeptides Nos 1, 2 and 3 from Figure 4. The last
heptapeptide, synthesized again with added terminal alanines as
nonapeptide No. 4, was identified by panning on GST-MN and
eluted with acetazolamide. This last peptide has affinity to the
active site of MN/CA IX carbonic anhydrase. We synthesized
these peptides of 7 + 2 aa and tested them in competition ELISA
and in cell adhesion inhibition. Both tests yielded essentially
consistent results: peptide No. 2 showed the highest activity,
peptide No. 1 was less active, peptide No. 3 was marginally posi-
tive only in ELISA, and peptide No. 4 was inactive.
DISCUSSION
Purification of transmembrane proteins like MN/CA IX often
poses technical problems because they tend to form aggregates
with other membrane proteins due to their hydrophobic TM
segments. To avoid this, we engineered truncated MN/CA IX
DICDTM, which is secreted into the medium. Indeed, truncated
MN/CA IX was obtained in higher purity than MN/CA IX+
(Figure 1). Unfortunately, this protein was of little use for our
purposes, since it was inactive in the cell adhesion test (Figure 2).
Such a situation has also been described for other cell adhesion
molecules: their shed, shortened form either assumes an inactive
conformation, or it adsorbs to hydrophobic plastic ‘upside down’,
while complete proteins adsorb by hydrophobic TM segments in
the ‘correct’ position.
MN/CA IX protein forms oligomers of 150 kDa, linked by
disulphidic bonds (Pastorekova et al, 1992; Závada et al, 1993). It
was not known whether these are homo- or hetero-oligomers.
Figure 1 suggests that these are probably homo-oligomers, most
likely trimers, since on the gel stained with Coomassie blue no
additional bands of intensity comparable to two bands specific for
MN/CA IX appeared. It is also unlikely that there could exist an
additional protein co-migrating with one of the two major MN/CA
IX bands, since the intensity of their staining on the gel and on
Western blots is well comparable.
There can be no doubt on the specificity of cell attachment to
purified MN/CA IX+. It is abrogated by specific mAb M75, at a
dilution 1:1000 of ascites fluid. This is a correction to our previous
report (Závada et al, 1997) in which we observed that MN/CA IX
produced by vaccinia virus vector and fusion protein GST-MN
support cell adhesion, but we did not realize that GST anchor itself
contains another binding site, which is not blocked by M75.
mAb M75 reacts excellently with MN/CA IX under any circum-
stances – with native antigen on the surface of living cells, with
denatured protein on Western blots and with antigen in paraffin
sections of biopsies fixed with formaldehyde, suggesting that the
epitope is small and contiguous. In competition ELISA (Figure 3)
the smallest sequence reactive with M75 was 7 + 2 aa, but the
affinity between M75 and tested peptides strongly depended on
their molecular weight. Complete MN/CA IX was 1 000 000 ´
more active than the smallest serologically active peptide in terms
of weight/volume concentration. In terms of molar concentration
this difference would be 150 000 000 ´. Oligopeptides of interme-
diate size also showed intermediate activities. It remains to be
elucidated whether such differences in activity are due to the
conformation depending on the size of the molecule, or to the fact
that complete MN/CA IX contains several copies of the epitope,
but the smallest molecule only one.
Considering the possibility that the epitope is identical with the
cell adhesion structure in MN/CA IX, we can understand why we
failed to detect inhibition of cell adhesion by the oligopeptides.
The binding site is just not as simple as the prototype peptide,
RGD (Piersbacher and Ruoslahti, 1984).
Naturally, one can argue that the size of MN/CA IX is about the
same as of immunoglobulin molecule, and that binding of M75 to
its epitope may sterically hinder a different sequence of cell attach-
ment site. This objection has been made unlikely by blocking of
both M75 epitope and of cell binding site by nonapeptides 7 + 2
aa. This result (Figure 4) strongly suggests that the epitope and the
binding site are indeed identical.
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MN/CA IX and its PG region in particular appears to be a poten-
tial target molecule for therapy for the following reasons: (i) it is
exposed on the cell surface; (ii) it is present in high percentage of
certain human carcinomas; (iii) it is normally expressed MN/CA IX
in the mucosa of alimentary tract which is not accessible to circu-
lating antibodies, in contrast with the tumours; (iv) it is not shed (or
only minimally) into the body fluids; (v) the motif GEEDLP is
repeated 18 ´ on the surface of every MN/CA IX molecule.
Oligopeptide display libraries are being employed in the first steps to
develop new drugs (Winter, 1996). Selected oligopeptides can serve
as lead compounds for the computerized design of new molecules,
with additional properties required from a drug (DeCamp et al,
1996).
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